RxDoctor Payments DataLook up a doctor →

Neil Nagaria, MD

Gastroenterology · Toms River, NJNPI 1760401749

Payments from drug & device makers

$441,903in general payments, 2019–2025

Across 775 payments — averaging $570.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$302K
  • Bausch Health US, LLC$65K
  • Madrigal Pharmaceuticals$64K
  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$664
  • plus $7K from 32 others

What the payments were for

  • Consulting fees$9681%
  • Speaking & faculty fees$57,40877%
  • Travel & lodging$2,8594%
  • Food & beverage$13,31818%
  • Education$1220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$441,903 in reported general payments places this provider in the 95th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$518,624
Medicare patients
1,462
Services billed
4,985

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab15$399,456
CreonLipase/Protease/Amylase32$117,402
LinzessLinaclotide144$108,535
XifaxanRifaximin25$72,746
ZenpepLipase/Protease/Amylase14$53,760
RezdiffraResmetirom11$43,503
Dexlansoprazole DrDexlansoprazole77$35,969
RybelsusSemaglutide25$26,470
TrulancePlecanatide18$16,816
OzempicSemaglutide15$14,013
Pantoprazole Sodium924$12,085
Mesalamine28$9,238
Colesevelam Hcl117$5,986
Lubiprostone44$5,685
Ursodiol14$4,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$575$399,45615 claims
AbbVieCreon, Linzess$2,415$225,936176 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$1,180$89,56143 claims
Aimmune Therapeutics, Inc.Zenpep$506$53,76014 claims
Madrigal PharmaceuticalsRezdiffra$63,773$43,50311 claims
Novo NordiskRybelsus, Ozempic$137$40,48340 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$664$3,59212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →